Avidity Biosciences (RNA)

Company Profile

avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated

Company profile

Ticker

RNA

Exchange

NASDAQ

Website

aviditybio.com

CEO

Sarah Boyce

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

Avidity Biosciences LLC, Avidity NanoMedicines LLC

SEC CIK

0001599901

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

IRS number

461336960

RNA stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Entry into a Material Definitive Agreement

8 Nov 23

Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights

8 Aug 23

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights

8 Aug 23

8-K

Regulation FD Disclosure

10 Jul 23

8-K

Submission of Matters to a Vote of Security Holders

9 May 23

Latest ownership filings

View all

Financial summary

Financial statements Chart RNA financial data

Quarter (USD)	Sep 23	Jun 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	85.95 mm	85.95 mm	85.95 mm	85.95 mm	85.95 mm	85.95 mm
Cash burn (monthly)	22.74 mm	4.83 mm	19.54 mm	18.51 mm	12.26 mm	14.56 mm
Cash used (since last report)	48.81 mm	10.37 mm	41.94 mm	39.72 mm	26.32 mm	31.26 mm
Cash remaining	37.13 mm	75.57 mm	44.00 mm	46.22 mm	59.62 mm	54.69 mm
Runway (months of cash)	1.6	15.6	2.3	2.5	4.9	3.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2023

RNA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	143	143	–
Opened positions	18	25	-28.0%
Closed positions	18	19	-5.3%
Increased positions	62	64	-3.1%
Reduced positions	40	32	+25.0%

13F shares	Current	Prev Q	Change
Total value	519.52 bn	906.45 bn	-42.7%
Total shares	89.24 mm	89.94 mm	-0.8%
Total puts	1.30 k	40.30 k	-96.8%
Total calls	45.40 k	5.80 k	+682.8%
Total put/call ratio	0.0	6.9	-99.6%

Largest owners	Shares	Value	Change
FMR	11.11 mm	$70.91 bn	+4.6%
RTW Investments	6.69 mm	$42.68 bn	0.0%
T. Rowe Price	6.62 mm	$42.21 bn	-1.0%
Ra Capital Management	6.42 mm	$40.94 bn	0.0%
BLK Blackrock	5.79 mm	$36.92 bn	+0.5%
Cowen And	5.63 mm	$35.91 bn	0.0%
Cowen Financial Products	5.19 mm	$115.13 mm	0.0%
STT State Street	4.16 mm	$26.54 bn	-32.8%
Vanguard	4.01 mm	$25.61 bn	+1.2%
Avoro Capital Advisors	2.51 mm	$16.01 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
STT State Street	4.16 mm	-2.03 mm	-32.8%
Cormorant Asset Management	1.76 mm	-850.00 k	-32.5%
Millennium Management	740.50 k	+695.36 k	+1540.4%
Baker Bros. Advisors	166.35 k	-633.10 k	-79.2%
Adage Capital Partners GP, L.L.C.	1.30 mm	+550.00 k	+73.3%
FMR	11.11 mm	+491.57 k	+4.6%
JPM JPMorgan Chase & Co.	970.70 k	+420.70 k	+76.5%
Casdin Capital	1.25 mm	+400.00 k	+47.1%
Alliancebernstein	527.62 k	+362.22 k	+219.0%
BAC Bank Of America	360.21 k	-326.31 k	-47.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RNA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Sep 23	W. Michael Flanagan	Stock Option Common Stock	Grant	Acquire A	No	No	6.57	72,000	473.04 k	72,000
11 Sep 23	Teresa McCarthy	Stock Option Common Stock	Grant	Acquire A	No	No	6.57	54,000	354.78 k	54,000
11 Sep 23	MacLean Michael F	Stock Option Common Stock	Grant	Acquire A	No	No	6.57	74,000	486.18 k	74,000
11 Sep 23	Boyce Sarah	Stock Option Common Stock	Grant	Acquire A	No	No	6.57	200,000	1.31 mm	200,000
15 Jun 23	Boess Carsten	Stock Option Common Stock	Grant	Acquire A	No	No	12.48	22,000	274.56 k	22,000